Botanix Pharmaceuticals Limited Overview
Botanix Pharmaceuticals is an ASX-listed, US-operated, single-product commercial dermatology company. Its sole marketed asset, Sofdra (sofpironium) topical gel 12.45%, is the first and only new chemical entity approved by the US FDA for primary axillary hyperhidrosis — an underserved condition the company sizes at roughly 10 million US patients, of whom about 3.7 million actively seek treatment. Botanix acquired global rights to sofpironium bromide from Brickell Biotech in 2022, secured FDA approval in June 2024, and launched nationally with a field sales force in February 2025. The commercial model pairs a dermatology-focused sales team with a proprietary closed-loop fulfilment platform (single specialty pharmacy, direct-to-patient shipping, prior-authorisation support) that bypasses wholesalers. FY26 net revenue reached A$33.8 million on A$152.8 million gross sales, but losses, a deeply discounted 2026 equity raise, a going-concern material uncertainty and a ~94% share-price decline since mid-2025 frame Botanix today as a high-growth, capital-constrained micro-cap.
Company's own description (FY26 Annual Report, paraphrased)
In its FY26 Directors' Report, Botanix characterises itself as a revenue-generating pharmaceutical company with an FDA-approved product, accelerating commercial traction, a proven fulfilment platform, and the infrastructure required for continued expansion. It positions Sofdra as a novel, safe and effective solution for primary axillary hyperhidrosis, citing its mechanism (blocking acetylcholine at the M3 receptor in the sweat gland), its rapid metabolism (designed to reduce systemic anticholinergic adverse events), and its proprietary applicator, which limits drug contact with the hands. It describes hyperhidrosis as the third-largest dermatologic condition in the US after acne and atopic dermatitis, and states that FY26 marked its transition from a development-stage biotechnology company to a revenue-generating commercial pharmaceutical business.
What the company does
Botanix in-licensed and now commercialises a single topical anticholinergic, Sofdra, in the United States. It does not manufacture: active pharmaceutical ingredient (API) is currently sourced from Kaken Pharmaceutical (Japan), finished goods are made at a contract manufacturing site in Canada, and dispensing occurs through a single specialty pharmacy network (identified in company footnotes as SendRx). Botanix's own value-add is commercial: sales force promotion to dermatologists, payer contracting, patient services, prior authorisation support, co-pay buy-down, refill management and marketing.
Business and revenue model
| Revenue stream | Mechanism | FY26 contribution (AUD) | Source |
|---|---|---|---|
| Sofdra net product sales (US) | Product shipped to patients against prescriptions via the Botanix Fulfilment Platform; revenue recognised at delivery, net of rebates, chargebacks, co-pay support and government program deductions (gross-to-net) | 33,219,460 | FY26 AR, Note 3 |
| Net royalties (Japan / South Korea) | Royalties received from Kaken Pharmaceutical on Ecclock (sofpironium bromide gel 5%) in Japan and via Kaken's South Korean sublicensee Dongwha Pharm; presented net of royalties Botanix must pay onward under the sofpironium asset purchase agreement (Botanix acts as agent) | 582,046 (1,293,437 received less 711,391 paid) | FY26 AR, Note 3 |
| Services / subscription / licensing upfronts | None recognised in FY26 | 0 | FY26 AR, Note 3 |
Mix for FY26: ~98.3% product, ~1.7% net royalty/licensing; 0% services or subscriptions. Revenue is entirely "goods transferred at a point in time".
Value-chain position
Botanix sits at the brand-owner/commercialiser layer of the specialty pharmaceutical value chain: IP owner and NDA holder, outsourcing chemistry (API), formulation and fill-finish to third parties, and outsourcing dispensing to a partner pharmacy while retaining control of the patient journey and data. Removing the wholesaler and consigning inventory directly to the pharmacy is presented by the company as a source of supply-chain cost savings and real-time data visibility (FY25 and FY26 Annual Reports).
Customer types and end-markets
| Stakeholder | Role | Notes |
|---|---|---|
| Patients with primary axillary hyperhidrosis (age 9+) | End user | ~10 million US patients; ~3.7 million actively seeking treatment (company estimate, adapted from 2019 Cowen analysis) |
| Dermatologists, PAs and NPs | Prescribers | Unique prescribers grew from 1,075 (Q3 FY25 exit) to 2,316 (Q4 FY25 exit); later counts not disclosed |
| Commercial payers / PBMs, Medicare Part D, Medicaid | Reimbursement | Payer contracts require confirmation of diagnosis and, for some, prior trial of aluminium chloride (FY25 AR) |
| Specialty pharmacy (SendRx) | Dispensing partner | Single pharmacy network under the Botanix Fulfilment Platform |
| Kaken Pharmaceutical / Dongwha Pharm | Licensee / sublicensee | Royalty-paying partners in Japan and South Korea; Kaken is also current API supplier |
End-market: US prescription medical dermatology (hyperhidrosis segment); secondary exposure to Japanese and Korean hyperhidrosis markets via royalties.
Independent characterisation
Botanix is best understood as a single-asset US specialty pharma launch vehicle funded from the Australian equity market. Its operating metrics show genuine product-market traction — FY26 prescriptions shipped rose 527% to 105,794 and Q4 FY26 set a monthly record of 12,895 shipments — but the economics are dominated by a very low net-to-gross realisation (average gross-to-net "yield" of 22% in FY26, meaning roughly A$0.22 of net revenue per A$1 of gross sales), heavy promotional spend (A$52.0M product sales and marketing expense in FY26 versus A$33.8M of revenue), and dependence on a single API source in Japan. The investment case therefore rests on three levers: (i) improving gross-to-net toward the 30–40% management target, (ii) reducing cost of goods via the second API supplier (Piramal), and (iii) leveraging the fulfilment platform with additional in-licensed or acquired products. The balance-sheet position — A$36.6M cash against A$24.9M of secured Kreos debt at fair value and an auditor-noted material uncertainty on going concern — means execution must occur against a short funding runway.
Strategy
Stated strategic themes (FY26 Annual Report, paraphrased)
Management lists its priorities as: (1) continuing growth of the Sofdra franchise and commercial momentum; (2) exploring acquisitions that could leverage Botanix's sales force and fulfilment capability; (3) engaging with inbound licensing and acquisition interest; (4) strengthening the Sofdra IP estate; (5) onboarding Piramal as an alternate API supplier for resilience and long-term margin; (6) improving cash flow and working-capital management; (7) optimising resource allocation and sales-force alignment for efficiency and profitability; and (8) validating that the fulfilment platform can support additional products. The overarching message is a pivot from "accelerate the launch" (FY25) to "disciplined, sustainable growth toward profitability" (FY26).
Initiative register — last 24 months
| Date | Initiative | Type | Target / outcome | Status |
|---|---|---|---|---|
| Dec 2024 | Patient Experience Program with International Hyperhidrosis Society | Launch | Validate telehealth + fulfilment; first revenue | Completed |
| Dec 2024 | First payer contracts | Market access | Coverage with diagnosis / prior aluminium chloride step | Completed |
| Feb 2025 | National launch with 27 sales professionals | Commercial | First full quarter TRx 13,647 (Q4 FY25) | Completed |
| Q4 FY25–Oct 2025 | Sales force expansion 27→33→50 | Commercial | Funded mainly by reallocating sales & marketing budget | Completed; later reversed in part |
| Jun 2025 | Kreos US$30M debt facility | Financing | Working capital, platform expansion | Tranche A drawn; Tranche B status after 1 Oct 2026 not disclosed |
| FY25–FY26 | Spanish-language patient materials | Marketing | Reach ~41M US Spanish speakers | In development (FY25 AR) |
| FY25–FY26 | Medical education: JAAD publication, Fall Clinical, AAD Innovation Academy posters; speaker programme; "Summer of Sweat" HCP events; Hyperhidrosis Awareness Month support | Medical affairs | Physician adoption | Ongoing |
| Feb 2026 | A$45M equity raise | Financing | API purchases, second supplier, marketing, working capital | Completed (EGM 1 Apr 2026) |
| Mar 2026 | Kaken API agreement renegotiation | Supply / cash | Defer ~A$15M of purchases; no API purchase before Dec 2027 | Completed |
| Apr 2026 | Piramal second API supplier | Supply / margin / tariff | 25–40% lower long-term COGS; US site; onboarding complete 2028 | In progress |
| Jul 2026 | EPO intention to grant (applicator) and US Notice of Allowance (drug substance) | IP | Protection to 2039/2040 | Pending formal grant/issue |
| 31 Jul 2026 | Sales force resizing 50→39 | Cost programme | ~12% lower operating costs; 94% coverage retained | Implemented |
| Ongoing | Platform product acquisition / in-licensing | Business development | Add revenue-accretive dermatology product | No transaction announced |
| Ongoing | Ex-Asia sublicensing of sofpironium (e.g., Europe) | Licensing | Upfronts, milestones, royalties | No transaction announced |
ESG commitments: none formal; the company has committed to develop an ESG framework in future (FY25 and FY26 ARs).
Medium-term targets and guidance
| Item | Guidance | Source |
|---|---|---|
| Gross-to-net yield | Target average 30–40% over time; GTN expected to continue rising through 1H FY27 | FY25 AR; Q2 FY26 4C; FY26 AR |
| Revenue | Expected to rise quarter on quarter | FY26 AR (going concern discussion) |
| Operating costs | ~12% reduction from 31 Jul 2026 | FY26 AR |
| API purchases | None expected before December 2027 | FY26 AR |
| COGS | 25–40% long-term reduction once Piramal onboarded (2028) | FY26 AR |
| Profitability | "Clear path to profitability" asserted (FY25 AR, Q2 FY26 4C); no date or quantified EBITDA target given | — |
| Revenue / earnings guidance | No numerical revenue or EBITDA guidance | — |
Products & Services
Marketed product: Sofdra (sofpironium) topical gel, 12.45%
| Attribute | Detail |
|---|---|
| Indication | Primary axillary hyperhidrosis (excessive underarm sweating) in adults and children aged 9 years and older |
| Regulatory status | FDA-approved 18 June 2024 (NDA); first and only NCE approved by FDA for this indication |
| Mechanism | Anticholinergic; targets M3 muscarinic receptor in eccrine sweat glands, blocking acetylcholine signalling to reduce sweat at source; designed as a "soft" drug rapidly metabolised once systemically absorbed |
| Formulation / device | Topical gel dispensed via proprietary pump bottle with applicator that avoids hand contact (applicator subject of the 2026 EPO intention to grant) |
| Clinical basis | Two pivotal Phase 3 CARDIGAN studies (>700 patients) met all primary and secondary endpoints at day 43 (Gravimetric Sweat Production and HDSM-Ax-7 patient-reported severity); ~300 patients in a separate 48-week safety study; most adverse events mild-to-moderate and transient; Phase 3 data published in the Journal of the American Academy of Dermatology, vol. 93, July 2025 |
| Key safety label points | Contraindicated in glaucoma, severe ulcerative colitis, myasthenia gravis, Sjögren's syndrome; warnings for blurred vision and urinary retention; common AEs include dry mouth, blurred vision, application-site reactions, mydriasis, urinary problems; product is flammable |
| Target customer | US dermatologists, dermatology PAs/NPs; patients with confirmed PAH, typically after trying aluminium chloride (payer step) |
| Launch | Early-access Patient Experience Program Dec 2024; full national launch with sales force February 2025 |
| Pricing model | Wholesale acquisition cost not disclosed in sources reviewed. Derived economics for FY26: gross sales of ~A$1,444 per prescription shipped and net revenue of ~A$314 per prescription (A$152.8M and A$33.2M over 105,794 TRx) |
| Channel | Botanix Fulfilment Platform (single specialty pharmacy, direct-to-home shipping, auto-refill, PA support, co-pay buy-down); wholesaler removed |
| Adherence | Patients averaged more than 5 fills (FY26 AR) vs an industry average of fewer than 2 fills per year for topicals; 95% adherence among auto-refill enrolees and 79% overall (FY25 AR) |
| Patent life | Existing patents plus European applicator patent (expected to May 2039) and US crystalline-form drug-substance patent (expected to May 2040) once issued |
| Physician sentiment | May 2026 survey of 21 US dermatology HCPs: 100% expect to maintain or increase prescribing; earlier Q2 FY26 survey: 90% expected to increase prescribing |
Licensed-out product: Ecclock gel 5% (sofpironium bromide)
| Attribute | Detail |
|---|---|
| Territory / partner | Japan — Kaken Pharmaceutical (licensee inherited via Brickell); South Korea — Dongwha Pharm (Kaken sublicensee) |
| Status | Marketed in Japan since 2020; approved in South Korea August 2025 and launched January 2026 |
| Economics to Botanix | Royalties received (A$1.29M FY26) net of royalties paid onward (A$0.71M FY26); Botanix expects minimal revenue from the Korean sublicense |
| Strategic note | Botanix retains the right to sublicense sofpironium bromide outside Asia, with potential upfronts, milestones and royalties |
Platform / service capability: Botanix Fulfilment Platform
| Attribute | Detail |
|---|---|
| Description | Closed-loop prescription fulfilment: single specialty pharmacy network, dedicated support team for prior authorisation, co-pay management, direct-to-patient shipment, personal refill follow-up, real-time data feed to Botanix |
| Launch | Fully developed and tested before December 2024 Patient Experience Program |
| Monetisation | Not a separately priced service; drives GTN and refill economics. Company is assessing acquisition opportunities where the platform could improve another product's GTN and refill rate |
| Telehealth component | Digital telehealth platform for diagnosis of hyperhidrosis deployed (FY25); certain executive incentive tranches tied to telehealth-derived revenue remain unvested at FY26 |
Legacy development pipeline
Pre-2022 programmes (Permetrex-based synthetic cannabidiol topicals BTX 1503, BTX 1204, BTX 1308; antimicrobial BTX 1801) are no longer referenced in the FY25 or FY26 Annual Reports' principal activities. FY26 reported zero research expense (FY25: A$0.14M), confirming that internal R&D has effectively ceased. Their current status is not publicly disclosed in the sources reviewed; the analyst treats them as discontinued or dormant.
Lifecycle and business development
The FY26 STI scorecard rewarded management for generating at least one feasible Sofdra lifecycle-extension concept (achieved) but the target of a signed term sheet for a late-stage or marketed product was not achieved (0%). No new product has been added as of the report date.
Financial Narrative
All figures A$ millions unless stated; fiscal years end 30 June.
Income statement
Notes and discrepancies:
-
FY22 and FY23 "net income" values are those shown in the remuneration report's five-year table, which labels them "loss for the year attributable to owners"; for FY24 the same table shows A$13.71M, which equals total comprehensive loss rather than the A$13.87M statutory loss after tax. FY22–FY23 figures may therefore also be comprehensive-loss figures.
-
The FY25 Appendix 4E states the FY24 comparative "loss from ordinary activities after tax" as A$32.03M, which conflicts with the A$13.87M in the FY25 audited income statement. The audited statement is preferred; the discrepancy is unexplained in the documents reviewed.
-
EBIT derived as loss before tax plus finance expenses less interest income. FY25 EBIT includes a one-off A$5.11M cost of issuing debt (Kreos); FY26 includes a A$1.59M gain on fair-value movement of the Kreos liability.
-
Gross profit is a proxy: "materials and related expenses" is the closest line to COGS; Botanix does not present a gross profit subtotal.
Margins and growth (derived)
Revenue CAGR FY23–FY26 (3-year, derived): ~590% p.a., from A$0.10M to A$33.8M. A five-year CAGR is undefined because FY22 revenue was nil.
Commentary. The key inflection is FY25→FY26: revenue rose 5.9x while total operating expenses rose only ~11% (A$94.1M to A$104.8M), so the operating margin improved from -1,529% to -201%. Gross margin proxy improved to 57.6% as volume absorbed fixed manufacturing costs, though it remains depressed relative to mature branded dermatology (Journey Medical reported 66.2% for CY2025) because net price realisation is so low: at a 22% GTN yield, materials cost per unit consumes a much larger share of net revenue than it would at the 30–40% GTN management targets. Share-based payments halved to A$10.4M, contributing ~A$10M of the A$16.6M year-on-year reduction in net loss. Product sales and marketing (A$52.0M) remains the dominant cost and exceeded revenue by 1.5x in FY26. The post-balance-date sales-force resizing (~12% cost reduction from 31 July 2026) and deferral of API purchases are the principal levers for FY27 loss reduction.
Balance sheet (as at 30 June)
Sources: FY25 AR (FY24 comparatives; FY23 cash and opening equity from cash flow and equity statements); FY26 AR. Debt is the Kreos loan carried as "financial liabilities at fair value through profit or loss".
Commentary. Net cash has fallen from A$79.3M (FY24) to A$10.9M (FY26). Inventory has become a major use of capital (A$31.4M, of which A$19.3M raw materials, essentially pre-purchased API), equal to 86% of year-end cash. Intangibles comprise only the sofpironium licence, amortised straight-line over ~16 years. Equity has been eroded by losses (accumulated losses A$247.0M at FY26) despite A$79.9M of new contributed equity across FY25–FY26.
Cash flow
Note: the December 2025 cancellation of 6,928,586 erroneously issued shares was a nil-consideration buy-back with no cash outflow.
Commentary. FY26 operating cash burn of A$64.6M improved 18% year on year, and the quarterly trajectory is more informative: A$28.4M (Q4 FY25, inflated by A$11.2M inventory), A$13.1M (Q1 FY26), A$17.2M (Q2), A$23.3M (Q3, incl. A$9.7M API purchase) and A$10.6M (Q4). Stripping the API purchase, Q3 underlying burn was ~A$13.6M. With no API purchases expected before December 2027 and the sales-force resizing, a sub-A$10M quarterly burn in FY27 is plausible but not guided; quarter-end cash of A$36.6M equates to roughly 3–4 quarters at Q4 FY26 burn rates, which explains the going-concern material uncertainty.
Ratios (derived)
Not meaningful: net debt/EBITDA (net cash, negative EBITDA); interest coverage (EBIT of -A$68.0M vs finance expense of A$2.8M = -24x); cash conversion cycle (inventory days distorted by multi-year API stockpile; payables include marketing accruals).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 0 | 0.10 | 0.60 | 5.76 | 33.80 |
Materials and related expenses (COGS proxy) | — | — | 0 | 3.44 | 14.33 |
Gross profit (revenue less materials; derived) | — | — | 0.60 | 2.32 | 19.47 |
Product sales and marketing expense | — | — | 0 | 38.46 | 52.01 |
Employee and related expenses | — | — | 2.70 | 12.51 | 14.17 |
Share-based payments expense | — | — | 4.39 | 20.52 | 10.41 |
Research expenses | — | — | 1.81 | 0.14 | 0 |
Depreciation and amortisation | — | — | 0.07 | 2.26 | 2.32 |
Operating income / EBIT (derived) | — | — | -13.93 | -88.02 | -68.04 |
EBITDA (derived) | — | — | -13.86 | -85.76 | -65.72 |
Pre-tax income | — | — | -13.87 | -86.40 | -69.77 |
Net income (statutory loss after tax) | -12.98 | -8.92 | -13.87 | -86.40 | -69.77 |
EPS basic (A$ cents) | -1.35 | -0.79 | -0.92 | -4.68 | -3.22 |
EPS diluted (A$ cents) | -1.35 | -0.79 | -0.92 | -4.68 | -3.22 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Gross margin (proxy) | 100.0 | 40.3 | 57.6 |
Operating margin | -2,314 | -1,529 | -201 |
EBITDA margin | -2,302 | -1,490 | -194 |
Net margin | -2,304 | -1,501 | -206 |
Revenue growth YoY | 485 | 857 | 487 |
Balance Sheet and Per-Share Data
| Metric (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Total assets | — | 112.46 | 129.10 | 105.98 |
Cash and cash equivalents | 10.25 | 79.31 | 64.97 | 36.63 |
Inventory | — | 1.21 | 28.08 | 31.35 |
Trade and other receivables | — | 0.82 | 3.20 | 6.64 |
Intangible assets (sofpironium licences) | — | 29.49 | 28.12 | 24.88 |
Goodwill | — | 0 | 0 | 0 |
Short-term debt (Kreos, fair value) | — | 0 | 8.82 | 13.82 |
Long-term debt (Kreos, fair value) | — | 0 | 22.07 | 11.03 |
Total debt excl. leases | — | 0 | 30.89 | 24.85 |
Lease liabilities | — | 0 | 1.22 | 0.92 |
Net debt (negative = net cash; incl. leases) | — | -79.31 | -32.86 | -10.86 |
Total liabilities | — | 3.73 | 47.80 | 42.45 |
Total equity | 22.95 | 108.73 | 81.30 | 63.52 |
Working capital | — | 79.17 | 74.67 | 49.30 |
Net tangible assets per share (A$ cents) | — | 4.38 | 2.71 | 1.41 |
Cash Flow
| Metric (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Receipts from customers | — | 1.06 | 3.95 | 30.96 |
Operating cash flow | — | -8.13 | -78.58 | -64.60 |
Capex (plant and equipment) | — | -0.11 | -0.29 | 0 |
Payments for intangibles | — | -17.89 | -0.76 | 0 |
Free cash flow (OCF less capex; derived) | — | -8.24 | -78.87 | -64.60 |
Free cash flow incl. intangibles (derived) | — | -26.13 | -79.63 | -64.60 |
Equity issued (gross proceeds) | — | 100.85 | 40.46 | 45.02 |
Debt drawn (Kreos convertible loan) | — | 0 | 28.40 | 0 |
Debt repaid | — | 0 | 0 | -2.76 |
Dividends paid | 0 | 0 | 0 | 0 |
Share buybacks (cash) | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ROE (%) — loss / average equity | — | -90.9 | -96.4 |
ROA (%) — loss / average total assets | — | -71.5 | -59.4 |
ROIC (%) — EBIT / (equity + debt + leases − cash) | — | -181.7 | -129.2 |
Current ratio (x) | 22.2 | 4.0 | 2.6 |
Debt / equity (x) | 0 | 0.38 | 0.39 |
Asset turnover (x) — revenue / average total assets | — | 0.05 | 0.29 |
Days sales outstanding (days, trade receivables / revenue) | — | 181 | 64 |
Days inventory (days, inventory / materials expense) | — | 2,980 | 799 |
Revenue by Region
| Region (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
United States — Sofdra net sales | 0 | 5.09 | 33.22 |
Japan and South Korea — net royalties | 0.60 | 0.66 | 0.58 |
Europe / rest of world | 0 | 0 | 0 |
Total | 0.60 | 5.76 | 33.80 |
Region growth (%)
| Region growth (%) | FY2025 | FY2026 |
|---|---|---|
United States (Sofdra) | — | 552 |
Japan / South Korea (net royalties) | 10.2 | -12.2 |
Share Price
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.06 | 0.13 | 0.35 | 0.32 | 0.019 |
Performance Window Details
| Performance window (approx., to late Sep 2026 at ~A$0.019) | Change |
|---|---|
1 year (vs ~A$0.12–0.145 in Aug–Oct 2025) | approx. -85% to -87% |
3 years (vs A$0.13 at 30 Jun 2023) | approx. -85% |
5 years (vs A$0.08 at 30 Jun 2021) | approx. -76% |
52-week range | A$0.018 – A$0.18 (Stocklight) |
Largest single-day move | -41.3% on 17 Feb 2026 (A$45M raise at A$0.06) |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | ~A$51M | — |
Enterprise value | ~A$40M | Market cap less FY26 net cash of A$10.9M (incl. leases) |
EV / Sales (FY26) | ~1.2x | EV / A$33.8M |
EV / Gross sales (FY26) | ~0.26x | EV / A$152.8M |
P / Book | ~0.8x | Market cap / A$63.5M equity |
Source Details
| Source | Rating / target | Comment |
|---|---|---|
Eulerpool (aggregated consensus, Aug 2026) | 12-month target A$0.42 | ~20x current price; likely includes stale targets |
TipRanks (latest listed rating) | Buy, A$2.00 target | Appears to predate the February 2026 raise; conflicts with Eulerpool consensus — discrepancy flagged |
TradingView (early 2026) | Range A$0.24–2.00 | Pre-raise |
Investing.com consensus (via Parqet, Apr 2026) | Revenue 27.71M (2026) and 56.43M (2027); EPS -0.02 (2026), -0.01 (2027) | Currency labelled USD by aggregator; FY26 actual (A$33.8M) exceeded the 2026 figure |
Capital Markets
| Item | Detail |
|---|---|
Dividend policy / history | No dividends ever paid or declared |
Buybacks | None for value; nil-consideration cancellation of 6.93M shares (Dec 2025) |
Options outstanding | 840,747,200, including 772,997,200 placement options at A$0.06 (table shows expiry 20 Apr 2029; the Directors' Report narrative states 31 Jan 2027 — discrepancy in the FY26 AR) |
Performance rights outstanding | 96,183,332 |
Warrants | 3,030,303 (Kreos) at A$0.33, expiring 10 Jun 2030 |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt | Kreos Capital VII secured facility: US$20M drawn June 2025 (Tranche A); US$10M Tranche B available to 1 Oct 2026 subject to conditions; part convertible at lender's option; financial, corporate and operating covenants including minimum cash. Carrying value at fair value A$24.85M (current A$13.82M; non-current A$11.03M) at 30 Jun 2026; A$2.76M principal repaid in FY26 |
Debt maturity profile | ~A$13.8M classified as due within 12 months; ~A$11.0M beyond 12 months. |
Analyst Conclusions
Management guidance (FY26 AR and Q4 FY26 report)
-
Net revenue expected to rise quarter on quarter.
-
GTN expected to continue rising through 1H FY27 toward a 30–40% long-term target.
-
Operating costs ~12% lower from 31 July 2026 after territory consolidation, with 94% physician coverage retained.
-
No API purchases before December 2027; Piramal onboarding complete in 2028 with 25–40% lower long-term COGS.
-
15% tariff (~US$10 per bottle) from 29 September 2026.
-
Active evaluation of product acquisitions and inbound licensing/acquisition interest.
-
No numerical revenue, EBITDA or breakeven guidance.
Consensus expectations
Aggregated consensus (Investing.com via Parqet) pointed to roughly a doubling of revenue into the following year (27.71M to 56.43M), with losses narrowing. These figures predate the FY26 result and should be treated as indicative only.
Bull case
-
Volume plus price compounding: Q4 FY26 TRx of 33,358 annualises to ~133,000; if GTN reaches 30% on stable gross price per script (~A$1,400), annualised net revenue would be ~A$56M (derived), with further upside from new prescribers in retained territories.
-
Margin structure improving fast: sales-force cut (~12% opex), no API cash outflow until December 2027 and the Piramal COGS reduction could bring quarterly operating cash burn close to breakeven within FY27–FY28, without further equity if Q4 FY26 trends persist.
-
Asset value exceeds market value: at an EV of ~A$40M (~0.26x gross sales) for an FDA-approved NCE with IP to 2040 and an operating US platform, a strategic acquirer or ex-US licensee could crystallise value well above the current price, consistent with management's track record of dermatology exits.
Bear case
-
Funding gap: A$36.6M cash, ~A$13.8M of Kreos debt classified as current, and a going-concern material uncertainty suggest another raise is likely within 12 months — probably at or below the current ~A$0.019, implying significant further dilution on top of ~773M A$0.06 options.
-
Unit economics may not converge: GTN has oscillated between 18% and 24% for five quarters; if payer mix and co-pay costs keep yields near 20%, gross margin and marketing efficiency may never support profitability on a single product.
-
Governance and policy overhangs: a potential second strike and board spill at the 2026 AGM, tariffs that add ~US$10 per bottle, and US drug-pricing uncertainty could constrain management bandwidth and deter strategic partners.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| Late Oct 2026 | Q1 FY27 Quarterly Activity Report / Appendix 4C | TRx growth post-territory cuts; GTN vs 22%; operating outflow vs A$10.6M; cash vs A$36.6M |
| Oct 2026 | Kreos Tranche B outcome | Whether US$10M was drawn, lapsed or renegotiated |
| ~Nov 2026 | 2026 AGM | Remuneration vote (second strike → spill resolution); new independent director appointments |
| 2H CY2026 | Tariff impact | COGS per unit after 29 Sep 2026 |
| FY27 | Capital raising / refinancing | Size, price, structure (equity vs debt restructure) |
| FY27 | US patent issuance and EPO grant/validation | Formal completion of July 2026 allowances |
| FY27 | Business development | Product acquisition, ex-Asia licence, or corporate approach |
| Q3 FY27 (Jan–Mar 2027) | Deductible-reset seasonality | Magnitude of GTN dip vs Q3 FY26 (18%) |
| 2027–2028 | Piramal onboarding progress | Regulatory filing for second API source; COGS trajectory |
Analyst verdict
Botanix has done the hard part that most ASX-listed biotechnology companies never achieve: it took an in-licensed molecule through FDA approval, built a US commercial organisation from fewer than ten people, and in its first full year generated A$152.8 million of gross sales and A$33.8 million of net revenue from more than 105,000 prescriptions. Clinical differentiation, physician enthusiasm and exceptional refill behaviour are all documented in the filings. The product is working.
The business model, however, is not yet working. Net realisation of roughly 22 cents per gross sales dollar, promotional spend exceeding revenue by half, and a materials line that still consumes over 40% of net revenue leave the company dependent on external capital. That dependence has been punished: the February 2026 raise at a 45.5% discount reset the share price, which has since fallen to around two cents, and the FY26 accounts carry a going-concern material uncertainty alongside a secured, covenant-bearing Kreos loan. Governance has added friction, with a 74% vote against remuneration, a non-majority-independent board, gross-revenue-based incentive hurdles and administrative errors.
The investment question is therefore one of runway versus inflection. Management has pulled the right levers — deferring API purchases, resizing the sales force toward its 39 productive territories, securing a lower-cost US-based API source and extending patent protection to 2040 — and Q4 FY26 delivered the best combination yet of revenue growth (+45% QoQ) and burn reduction (A$10.6 million). If Q1–Q2 FY27 demonstrate continued script growth with GTN trending toward 25–30% and quarterly burn below A$10 million, the current enterprise value of roughly A$40 million (about 1.2x net and 0.26x gross sales) materially undervalues an approved NCE with a functioning US platform, and a strategic transaction becomes credible. If GTN stalls and another deeply dilutive raise is required, equity holders will continue to fund the gap at punitive prices. On balance, Botanix is a high-risk, binary special situation: operationally promising, financially fragile, and governance-sensitive.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Committees | Independence (analyst view) |
|---|---|---|---|---|---|
Vincent Ippolito | Executive Chairman | 18 Jul 2019 | 40 years in pharma (30+ in dermatology). President & COO, Dermavant Sciences; CCO & EVP, Anacor (sold to Pfizer, US$5.2bn); CCO and other senior roles at Medicis (sold to Valeant, US$2.6bn, 2012); 17 years at Novartis (last role VP Dermatology, Paediatric & Respiratory) | — | Not independent (executive) |
Dr William (Bill) Bosch | Non-executive Director | 1 Jul 2016 (exec); NED from 1 Jul 2023 | 30+ years pharma R&D; CSO of iCeutica (SoluMatrix technology, four FDA-approved products); co-founder NanoSystems LLC and co-inventor of NanoCrystal technology (seven FDA-approved products) | Remuneration & Nomination (member) | Questionable: former executive and paid consultant until Oct 2024 |
Dr Stewart Washer | Non-executive Director | 21 Feb 2019 | Former exec chair Emyria; chair Orthocell; founding chair Cynata; chaired Hatchtech (sold for A$279M, 2015); former director iCeutica and AusBiotech | Chair, Remuneration & Nomination; member, Audit & Risk | Independent |
Danny Sharp | Non-executive Director | 22 Mar 2022 | 30+ years investment banking; Corporate Finance Executive Director at Canaccord Genuity (8 yrs); formerly Shaw and Partners, Lodge Partners; NED of Alcidion Group; CFA; B.Econ/Law | Chair, Audit & Risk; member, Remuneration & Nomination | Independent |
Dr Patricia Walker, MD PhD | Non-executive Director | 25 Aug 2025 | Practising dermatologist; former President & head of R&D at Brickell Biotech; CMO Kythera; EVP & CSO Allergan Medical Aesthetics; former Botanix Chief Medical Advisor | Audit & Risk (member from 26 Feb 2026) | Questionable: former paid adviser to Botanix and to the sofpironium vendor |
Executive Leadership Team
| Name | Title | Appointed | Prior roles / education |
|---|---|---|---|
Dr Howard (Howie) McKibbon | Chief Executive Officer | CEO 24 Aug 2023 (COO from Oct 2022) | SVP Sales & Marketing, Anacor; SVP Worldwide Commercial Operations, Dermavant; VP Dermatology & Immunology, Medicis; launched 15 products (11 dermatology). BA History (University of South Florida), MBA (Mercer University Stetson School), PharmD (Mercer Southern School of Pharmacy). Five-year contract |
Chris Lesovitz | Chief Financial Officer — USA | 4 Aug 2024 | Former CFO, Strata Skin Sciences; 20+ years healthcare/technology finance. Three-year contract |
Graeme Morissey | Chief Financial Officer — Australia | 26 Mar 2024 | 18+ years incl. Grant Thornton (Canada, Australia), KPMG, EY; multiple ASX CFO roles; CA ANZ. Contractor at A$125,000 p.a. |
Paul Seaback | Chief Operating Officer | COO from Q4 FY26 (announced 3 May 2026); joined Nov 2024 as CTO | 30+ years; CTO at Dermavant until its acquisition by Organon; roles at Gilead, Medicis, Hospira, Mayne, Novartis (Sandoz) |
Andrew Bickley | Company Secretary | 13 Oct 2025 | 15+ years governance; LLB (University of Essex); FGIA, FCG; also CoSec of Group 6 Metals |
Directors' Remuneration
| KMP | Salary/fees | Cash bonus | Other short-term (insurance + leave) | Super/401k | Options (SBP) | Performance rights (SBP) | Total | % performance-based |
|---|---|---|---|---|---|---|---|---|
V. Ippolito (Exec Chair) | 683,095 | 225,420 | 86,094 | 15,767 | 0 | 1,021,595 | 2,031,971 | 61.4 |
Dr H. McKibbon (CEO) | 667,915 | 154,287 | 82,241 | 15,766 | 0 | 1,060,748 | 1,980,957 | 61.3 |
C. Lesovitz (CFO US) | 495,200 | 162,009 | 86,052 | 16,239 | 340,430 | 448,729 | 1,548,659 | 61.4 |
G. Morissey (CFO AU) | 125,000 | 0 | 0 | 0 | 20,002 | 0 | 145,002 | 13.8 |
Dr W. Bosch (NED) | 85,000 | 0 | 0 | 0 | 0 | 220,485 | 305,485 | 72.2 |
Dr S. Washer (NED) | 100,000 | 0 | 0 | 0 | 0 | 220,485 | 320,485 | 68.8 |
D. Sharp (NED) | 100,000 | 0 | 0 | 0 | 0 | 220,485 | 320,485 | 68.8 |
Dr P. Walker (NED, part-year) | 74,375 | 0 | 0 | 0 | 247,517 | 0 | 321,892 | 76.9 |
Total KMP | 2,330,585 | 541,716 | 254,387 | 47,772 | 607,949 | 3,192,527 | 6,974,936 | 62.3 |
Major Shareholders
| Holder category | Holding | Source |
|---|---|---|
Substantial holders (≥5%) | None reported as of 18 August 2026 | FY26 AR (ASX additional information, per InvestSMART summary) |
Directors and KMP (30 June 2026) | 72,302,209 ordinary shares in aggregate (≈2.7% of an implied ~2.7bn shares; derived) | FY26 AR |
Largest individual insider holdings | Bosch 21.50M; McKibbon 18.07M; Ippolito 16.67M; Washer 7.83M (indirect); Sharp 6.08M (indirect) | FY26 AR |
Index inclusion | Held by S&P/ASX Small Ordinaries ETFs historically; S&P DJI March 2026 quarterly rebalance announcement listed in BOT filings (index deletion likely but not confirmed in sources reviewed) | TradingView; Stocklight |
Kreos Capital | 3,030,303 warrants at A$0.33 expiring 10 Jun 2030 | FY26 AR |
Competitive Landscape
Key Competitors
| # | Competitor | Product / modality | Positioning vs Sofdra |
|---|---|---|---|
| 1 | AbbVie | Botox (onabotulinumtoxinA) intradermal injections for severe axillary hyperhidrosis | Highly effective, long-lasting (months), but painful, in-office procedure with prior-authorisation hurdles; Sofdra positioned as non-invasive at-home option |
| 2 | Journey Medical Corp (NASDAQ: DERM) | Qbrexza (glycopyrronium tosylate 2.4% cloth) — the only other FDA-approved topical Rx anticholinergic for PAH | Closest direct competitor; Q2 CY2025 Qbrexza revenue ~US$6.9M per CFO commentary |
| 3 | Person & Covey and generic makers | Rx aluminium chloride hexahydrate (Drysol and generics) | First-line, cheap; payers often require trial before Sofdra — functions as both competitor and gatekeeper |
| 4 | Generic manufacturers | Oral glycopyrrolate / oxybutynin (off-label) | Low cost; systemic anticholinergic side effects |
| 5 | — | Microwave thermolysis device destroying sweat glands | Durable, procedure-based, cash-pay; complementary niche |
| 6 | Candesant Biomedical | Brella SweatControl patch (thermal, in-office) | Newer device option |
| 7 | Iontophoresis device makers (e.g., Dermadry, Hidrex, RA Fischer) | Tap-water iontophoresis | Mainly palmar/plantar; home use, time-intensive |
| 8 | Unilever, P&G, Church & Dwight and others | OTC "clinical strength" antiperspirants | Mass-market first step; compete for mild sufferers |
| 9 | Surgical providers | Endoscopic thoracic sympathectomy, local excision | Last resort; compensatory sweating risk |
| 10 | Maruho (Japan) | Rapifort wipes (glycopyrronium tosylate) | — |
Peer Comparison FY2026
| Metric | Botanix (FY26, A$) | Journey Medical (CY2025, US$) | Qbrexza (within Journey) |
|---|---|---|---|
Revenue | 33.8M | 61.9M | Not separately reported annually; ~US$6.9M in Q2 CY2025 (CFO comment) |
Revenue growth | +487% | +10% | Prescriptions +15% YoY in Mar–Apr 2025 (company commentary) |
Gross margin | ~57.6% (proxy, derived) | 66.2% | — |
SG&A / sales & marketing | A$52.0M sales & marketing (154% of revenue) | US$44.4M SG&A (72% of revenue) | — |
Profitability | EBITDA -A$65.7M (derived) | Adjusted EBITDA +US$2.9M | — |
R&D intensity | 0% | — | — |



